ArticleDiscover oncology2025
The predictive value of radiomics and deep learning for synchronous distant metastasis in clear cell renal cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Construction and validation of deep learning-based pathomics signature model for predicting postoperative recurrence of patients with clear cell renal cell carcinoma.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe objective of this research was to devise and authenticate a predictive model that employs CT radiomics and deep learning methodologies for the accurate prediction of synchronous distant metastasis (SDM) in clear cell renal cell carcinoma (ccRCC).
methodsA total of 143 ccRCC patients were included in the training cohort, and 62 ccRCC patients were included in the validation cohort. The CT images from all patients were normalized, and the tumor regions were manually segmented via ITK-SNAP software. Radiomic features were extracted via the FAE toolkit. The least absolute shrinkage and selection operator (LASSO) algorithm was employed to select features and build various machine learning models. Additionally, the largest cross-section of the tumor was cropped to train the deep learning model. Multiple deep learning models were trained to predict SDM in ccRCC patients. The results of the best machine learning model were then fused with those of the deep learning model to create a combined model.
resultsOf the 944 radiomic features identified, 15 were closely associated with SDM. With these 15 features, the support vector machine (SVM) model emerged as the most effective, demonstrating areas under the curve (AUC) of 0.860 and 0.813 in the training and validation cohort, respectively. Among the deep learning models, ResNet101 performed optimally, achieving AUC of 0.815 and 0.743 in the training and validation cohort, respectively. The combined model yielded an AUC of 0.863. Decision curve analysis suggested that the combined model offers superior clinical applicability.
conclusionThe model integrates radiomics and deep learning, showing significant potential in predicting SDM in ccRCC patients. It holds promise for supporting clinical decision-making, reducing missed diagnoses of SDM, and guiding patients in further enhancing their systemic examinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.